2024-515889-14-00已完成4 期
Bioequivalence study of GP-IMP-001 with regards to reference product
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
clinical department
Scientific
Gebro Pharma GmbH
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.2024-519640-32-00Institut De Recherches Internationales Servier IRIS36
已完成
4 期
Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®Type 1 Diabetes Mellitus2023-504509-36-00Biocon Sdn. Bhd.68
已完成
4 期
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment and prevention of Influenza.influenza2024-515436-76-00Adamed Pharma S.A.54
招募中
4 期
Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers2025-520572-25-00CCDRD Cooperative Clinical Drug Research and Development AG, Sopharma AD30
已完成
1 期
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Pfizer64